Key result
Designed small molecule cleaves DM1 RNA upon irradiation to improve cellular defects without toxicity.
Why the study?
Small molecules that cleave RNA in living cells have not been previously described, limiting approaches to control gene expression with better cellular permeability than oligonucleotides.
This study provides proof-of-concept that small molecules can be designed to specifically cleave RNA in living cells, offering a potential new therapeutic approach for RNA-mediated diseases like DM1.
Small-molecule RNA cleavage may bypass oligonucleotide uptake barriers; leaves open whether cellular activity yields therapeutic efficacy.
Antisense oligonucleotides and small interfering RNAs (siRNAs) control gene expression by triggering the degradation of a mRNA via recruitment of RNase H or the RNA-induced silencing complex (RISC), respectively.([1]) These approaches are hampered, however, by the poor cellular permeability of oligonucleotides. A small molecule approach to cleave RNA targets could obviate uptake issues. Several compounds can induce RNA cleavage in vitro,([2]) however, to the best of our knowledge no small molecules have been previously described to cleave RNA in living cells. Herein, we describe the development of a potentially general approach to design small molecules that specifically cleave an RNA in a living cell, affecting biological function. Specifically, a designed, modularly assembled small molecule that binds the RNA that causes myotonic dystrophy type 1 (DM1)([3]) was appended with a moiety that generates hydroxyl radicals upon irradiation. Cleavage of the transcript improves DM1-associated defects in cell culture, and compounds are non-toxic at an efficacious dose as determined by a MTT viability assay. This approach may allow for the site-specific cleavage and inactivation of other cellular RNAs.([4]) Compounds that bind to and cleave RNA have the potential to serve as chemical genetics probes of function or lead therapeutics with spatial and temporal control.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2012) studied Myotonic dystrophy type 1 (DM1). Small molecule that binds DM1 RNA appended with a moiety generating hydroxyl radicals upon irradiation was evaluated on Cleavage of the transcript and improvement of DM1-associated defects in cell culture. A designed small molecule successfully cleaved the RNA transcript causing myotonic dystrophy type 1 in living cells upon irradiation, improving DM1-associated defects without toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: